Edgewise Therapeutics
EWTX
140 hedge funds and large institutions have $1.83B invested in Edgewise Therapeutics in 2024 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 58 increasing their positions, 30 reducing their positions, and 21 closing their positions.
657% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $140K
93% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 30
57% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 21
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
10.38% more ownership
Funds ownership: 98.41% → 108.8% (+10%)
10% more capital invested
Capital invested by funds: $1.67B → $1.83B (+$159M)
9% more funds holding
Funds holding: 129 → 140 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$111M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$24.9M |
| 3 |
BlackRock
New York
|
+$14.8M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$14M |
| 5 |
Millennium Management
New York
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$32.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.6M |
| 3 |
PA
Perceptive Advisors
New York
|
-$8.08M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6.46M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.6M |
EWTX Hedge Fund Activity: Q2 2024 in Review
140 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q2 2024, worth a combined $1.83B — up 9.5% from $1.67B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new EWTX positions and 21 closed out — a net gain of 12 holders — while 58 added to existing stakes and 30 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $111M. The largest seller was Viking Global Investors, cutting an estimated $32.4M.
- 140 institutional investors held Edgewise Therapeutics (EWTX) as of Q2 2024, up from 129 in Q1 2024.
- Funds reported $1.83B of Edgewise Therapeutics stock for Q2 2024, up 9.5% quarter-over-quarter.
- 33 funds opened new Edgewise Therapeutics positions in Q2 2024 and 21 closed out, a net change of +12 holders.
- The largest Edgewise Therapeutics buyer in Q2 2024 was Novo Holdings A/S, an estimated $111M added.
- The largest Edgewise Therapeutics seller in Q2 2024 was Viking Global Investors, an estimated $32.4M sold.
Based on aggregated 13F filings for Q2 2024.